FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel triterpene derivatives of formula
and formula
active with respect to HIV, as well as HIV-mediated diseases, and to an intermediate compound of formula
In the general formula (I) R stands for H, substituted or non-substituted C1-6 alkyl, benzyl or substituted or non-substituted C4-5 cycloalkyl and preferably R is substituted with Ra; R' stands for H, substituted or non-substituted C1-6 alkyl, substituted or non-substituted C4-5 cycloalkyl, substituted or non-substituted C4-5 cycloalkenyl, substituted piperazinyl, substituted piperidinyl, substituted 8-azabicyclo[3.2.1]octane, 4-ethyl-2,2,6-trimethyl-1.3-dioxane, hexane-2,4-diol or (S)-1-((4aS,8aS)-octahydroisoquinolin-2(1H)-yl)-4-phenylbutan-2-ol and preferably R′ can be substituted with Ra; X is selected from a bond and -C(O)-; X1 is selected from -C(O)-, -C(O)2- or -C(O)NR"-; Z stands for -O-; Z1 stands for a bond; Z' stands for H; n equals 0; m equals 1,
″″ stands for a single bond; R1 stands for H; R2 stands for -C(=CH2)(CH3); Ra stands for cyano, phenyl, benzyl, ethyl, 3-isopropyl-5-methyl-1,2,4-triazole, -C(O)2R", -C(O)R", -CH2OR", -C(O)N(R)"2 or substituted or non-substituted C1-6 alkyl, where the substituent is selected from -OH, morpholinyl, benzyl, -COOMe, piperazinyl, optionally substituted with ethyl, piperidinyl, optionally substituted with methyl, -COOH, or benzyl; and each R" is independently selected from H, substituted or non-substituted C1-6 alkyl, methyl 3-methylbutanoate, 3-methylbutanic acid, 4-methylpentanic acid, methyl 4-methylpentanoate, methyl propionate, propanoic acid, 1-morpholinopropan-1-one, 1-(pyrrolidin-1-yl)propan-1-one, 4-ethylpiperazinyl, morpholinyl, piperidinyl, optionally substituted with -COOEt, pyrrolidinyl or benzyl. In formula (2A) XA1 stands for a bond or -C(O)-; XA2 stands for a bond, O or NH; RA1 stands for
Rb stands for substituted or non-substituted C1-6 alkyl; RA2 stands for substituted or non-substituted amine, substituted or non-substituted C4-5 cycloalkyl, substituted or non-substituted C4-5 cycloalkenyl, 4-ethyl-2,2,6-trimethyl-1,3-dioxane, hexane-2,4-diol, (S)-1-((4aS,8aS)-octahydroisoquinolin-2(1H)-yl)-4-phenylbutan-2-ol or substituted piperazinyl, substituted piperidinyl, substituted 8-azabicyclo[3.2.1]octane, and RA2 is preferably substituted with R'"; and each R'" represents substituted nitrogen-containing heterocycloalkyl (where alkyl is bound to a nitrogen atom in a heterocycle), where the substituent is selected from methyl, ethyl, -CN, phenyl, benzyl, 3-isopropyl-5-methyl-1,2,4-triazole, -COOH, -COOEt, -COOtBu, -CONHtBu, -CH2OH or phenyl.
EFFECT: obtaining novel triterpene derivatives.
14 cl, 1 tbl, 105 ex
Title | Year | Author | Number |
---|---|---|---|
C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | 2017 |
|
RU2716502C2 |
PROPENOATE BETULIN DERIVATIVES | 2012 |
|
RU2613554C2 |
METHOD OF PRODUCING BETULIN 28-HEMISUCCINATE | 2010 |
|
RU2435779C1 |
RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
VITAMIN D DERIVATIVE CONTAINING CYCLIC AMINE IN SIDE CHAIN | 2021 |
|
RU2819389C1 |
MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2508107C2 |
PIPERIDINE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2016 |
|
RU2730508C2 |
Authors
Dates
2015-08-27—Published
2010-07-05—Filed